anaxirone

Triglycidyl urazol (TGU), also known as anaxirone, is a small molecule triepoxide alkylating agent developed as an antineoplastic chemotherapeutic. It is a derivative of the triepoxide triglycidyl-triazinetrione (TGT). TGU functions by alkylating DNA, leading to cross-linking and inhibition of DNA synthesis, which results in cell death. It demonstrated broad-spectrum antitumor activity in preclinical models, including leukemias (P388, L1210) and solid tumors such as B16 melanoma and renal carcinoma. In clinical development, it was investigated for the treatment of small cell lung cancer and advanced ovarian carcinoma, but showed limited efficacy in these settings. Its primary dose-limiting toxicity is myelosuppression, and it is characterized by rapid plasma clearance following parenteral administration.

Brand names

Anaxirone

Other names

triglycidyl urazol1,2,4-triglycidyl urazoltriglycidylurazoleTGU